$66.95
0[0.00%]
At close: Apr 22
$66.95
0[0.00%]
PreMarket: 6:44PM EDT
Gilead Sciences
(NASDAQ:GILD)Gilead Sciences Stock (NASDAQ:GILD), Analyst Ratings, Price Targets, Predictions
Gilead Sciences Inc has a consensus price target of $85.65, established from looking at the 86 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, UBS, and Wells Fargo on April 19, 2024, April 17, 2024, and March 4, 2024. With an average price target of $86 between Oppenheimer, UBS, and Wells Fargo, there's an implied 28.45% upside for Gilead Sciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
UBS
Wells Fargo
Mizuho
Truist Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Gilead Sciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/19/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 56.83% | Oppenheimer | Hartaj Singh | $105 → $105 | Maintains | Outperform | Get Alert |
| 04/17/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 12.02% | UBS | Colin Bristow | $81 → $75 | Maintains | Neutral | Get Alert |
| 03/04/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 16.5% | Wells Fargo | Mohit Bansal | $84 → $78 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 34.43% | Mizuho | Salim Syed | $101 → $90 | Maintains | Buy | Get Alert |
| 02/22/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 22.48% | Truist Securities | Robyn Karnauskas | $91 → $82 | Downgrade | Buy → Hold | Get Alert |
| 02/14/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 12.02% | RBC Capital | Brian Abrahams | $76 → $75 | Maintains | Sector Perform | Get Alert |
| 02/12/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 19.49% | Barclays | Carter Gould | $85 → $80 | Maintains | Equal-Weight | Get Alert |
| 02/12/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 56.83% | Oppenheimer | Hartaj Singh | $115 → $105 | Maintains | Outperform | Get Alert |
| 02/07/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 16.5% | Cantor Fitzgerald | Olivia Brayer | $80 → $78 | Maintains | Neutral | Get Alert |
| 02/07/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 13.52% | RBC Capital | Brian Abrahams | $78 → $76 | Maintains | Sector Perform | Get Alert |
| 02/07/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 25.47% | Wells Fargo | Mohit Bansal | $90 → $84 | Maintains | Equal-Weight | Get Alert |
| 01/23/2024 | GILD | Buy Now | Gilead Sciences | $66.95 | 26.96% | Barclays | Carter Gould | $82 → $85 | Maintains | Equal-Weight | Get Alert |
| 11/14/2023 | GILD | Buy Now | Gilead Sciences | $66.95 | 15.01% | RBC Capital | Brian Abrahams | $78 → $77 | Maintains | Sector Perform | Get Alert |
| 11/09/2023 | GILD | Buy Now | Gilead Sciences | $66.95 | 12.02% | Deutsche Bank | James Shin | → $75 | Initiates | → Hold | Get Alert |
| 09/08/2023 | GILD | Buy Now | Gilead Sciences | $66.95 | 41.9% | B of A Securities | Geoff Meacham | $88 → $95 | Upgrade | Neutral → Buy | Get Alert |
| 09/06/2023 | GILD | Buy Now | Gilead Sciences | $66.95 | 35.92% | Truist Securities | Robyn Karnauskas | → $91 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2023 | GILD | Buy Now | Gilead Sciences | $66.95 | 6.05% | HSBC | Morten Herholdt | → $71 | Initiates | → Reduce | Get Alert |
| 08/04/2023 | GILD | Buy Now | Gilead Sciences | $66.95 | 31.44% | Morgan Stanley | Matthew Harrison | $86 → $88 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | GILD | Buy Now | Gilead Sciences | $66.95 | 25.47% | RBC Capital | Brian Abrahams | $83 → $84 | Maintains | Sector Perform | Get Alert |
FAQ
What is the target price for Gilead Sciences (GILD)?
The latest price target for Gilead Sciences (NASDAQ: GILD) was reported by Oppenheimer on April 19, 2024. The analyst firm set a price target for $105.00 expecting GILD to rise to within 12 months (a possible 56.83% upside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gilead Sciences (GILD)?
The latest analyst rating for Gilead Sciences (NASDAQ: GILD) was provided by Oppenheimer, and Gilead Sciences maintained their outperform rating.
When was the last upgrade for Gilead Sciences (GILD)?
The last upgrade for Gilead Sciences Inc happened on September 8, 2023 when B of A Securities raised their price target to $95. B of A Securities previously had a neutral for Gilead Sciences Inc.
When was the last downgrade for Gilead Sciences (GILD)?
The last downgrade for Gilead Sciences Inc happened on February 22, 2024 when Truist Securities changed their price target from $91 to $82 for Gilead Sciences Inc.
When is the next analyst rating going to be posted or updated for Gilead Sciences (GILD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on April 19, 2024 so you should expect the next rating to be made available sometime around April 19, 2025.
Is the Analyst Rating Gilead Sciences (GILD) correct?
While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a maintained with a price target of $105.00 to $105.00. The current price Gilead Sciences (GILD) is trading at is $66.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.